Muscarinic M1, M3, Nicotinic,GABAA and GABAB Receptor ...

More documents

Recommendations

Info

Figure-52 Scatchard analysis of [ 3 H] QNB binding against muscarinic M1 receptor antagonist, pirenzepine in the brainstem of control and experimental rats Table-52 Scatchard analysis of [ 3 H] QNB binding against muscarinic M1 receptor antagonist, pirenzepine in the brainstem of control and experimental rats Experimental groups Bmax (fmoles/mg protein) Kd (nM) Control 121 ± 5.7 0.33 ± 0.08 Diabetic a 85 ± 4.3 0.28 ± 0.07 D + IIH 67 ± 3.4 a, b 0.25 ± 0.03 C + IIH 42 ± 2.3 a, b, c 0.20 ± 0.06 Values are Mean ± S.E.M of 4-6 separate experiments. Each group consists of 6-8 rats. a b c p
Figure-53 Scatchard analysis of [ 3 H] DAMP binding against muscarinic M3 receptor antagonist, 4-DAMP mustard in the brainstem of control and experimental rats Table-53 Scatchard analysis of [ 3 H] DAMP binding against muscarinic M3 receptor antagonist, 4 DAMP mustard in the brainstem of control and experimental rats Experimental groups Bmax (fmoles/mg protein) Kd (nM) Control 13.8 ± 2.2 0.92 ± 0.03 Diabetic 22.8 ± 3.0 a 1.06 ± 0.05 a, b d, e D + IIH 35.0 ± 3.1 C + IIH a, b, c 43.7 ± 3.6 1.4 ± 0.01 d, e 1.8 ± 0.02 Values are Mean ± S.E.M of 4-6 separate experiments. Each group consists of 6-8 rats. a p
Page 2:
MUSCARINIC M1, M3, NICOTINIC, GABAA
Page 5 and 6:
ACKNOWLEDGEMENT To the Almighty God
Page 7 and 8:
Seema Chandran, Ms. Neema Ani Manga
Page 9 and 10:
ABBREVIATIONS 5-HIAA 5 Hydroxy indo
Page 11 and 12:
PFC Prefrontal cortex PLC Phospholi
Page 13 and 14:
GABAC Receptors 34 Glutamic Acid De
Page 15 and 16:
Behavioural response of control and
Page 17 and 18:
the cerebral cortex of control and
Page 19 and 20:
Muscarinic M1 receptor analysis Sca
Page 21 and 22:
REAL TIME-PCR ANALYSIS 81 Real Time
Page 23 and 24:
Real Time PCR analysis of GABAAα1
Page 25 and 26:
pancreas of control and experimenta
Page 27 and 28:
utilization is decreased in the bra
Page 29 and 30:
impairment, coma or seizure (Cryer,
Page 31 and 32:
achieving optimal blood sugar contr
Page 33 and 34:
OBJECTIVES OF THE PRESENT STUDY 1.
Page 35 and 36:
Literature Review Diabetes mellitus
Page 37 and 38:
12 Literature Review from the adren
Page 39 and 40:
14 Literature Review Hypoglycemic c
Page 41 and 42:
16 Literature Review respectively)
Page 43 and 44:
18 Literature Review in extracellul
Page 45 and 46:
20 Literature Review substrates in
Page 47 and 48:
22 Literature Review nucleus, altho
Page 49 and 50:
24 Literature Review al., 1990; Lev
Page 51 and 52:
26 Literature Review muscarinic M2
Page 53 and 54:
Signal transduction by muscarinic a
Page 55 and 56:
30 Literature Review nicotinic acet
Page 57 and 58:
GABAA Receptors 32 Literature Revie
Page 59 and 60:
34 Literature Review GABAB-mediated
Page 61 and 62:
36 Literature Review (Erlander et a
Page 63 and 64:
38 Literature Review which could be
Page 65 and 66:
40 Literature Review administration
Page 67 and 68:
42 Literature Review the hippocampu
Page 69 and 70:
44 Literature Review understanding
Page 71 and 72:
Confocal Dyes Rat primary antibody
Page 73 and 74:
antipyryl)-p-benzo quinoneimine. Th
Page 75 and 76:
was analyzed. Data was expressed as
Page 77 and 78:
ANALYSIS OF THE RECEPTOR BINDING DA
Page 79 and 80:
Taqman probes of muscarinic M1, M3,
Page 81 and 82:
Taylor, 1968). The islets were isol
Page 83 and 84:
Results BODY WEIGHT AND BLOOD GLUCO
Page 85 and 86:
60 Results IIH and C + IIH rats sho
Page 87 and 88:
Real Time-PCR analysis of muscarini
Page 89 and 90:
Real Time PCR analysis of SOD 64 Re
Page 91 and 92:
66 Results GABAAα1 receptor antibo
Page 93 and 94:
68 Results compared to diabetic gro
Page 95 and 96:
70 Results compared to diabetic rat
Page 97 and 98:
72 Results Muscarinic M3 receptor a
Page 99 and 100:
Muscarinic M3 receptor analysis 74
Page 101 and 102:
76 Results group, α7 nAChR mRNA si
Page 103 and 104:
78 Results diabetic rats. In C + II
Page 105 and 106:
Muscarinic M1 receptor analysis 80
Page 107 and 108:
Real Time-PCR analysis of α7 nAChR
Page 109 and 110:
Real Time PCR analysis of phospholi
Page 111 and 112:
HIPPOCAMPUS Total muscarinic recept
Page 113 and 114:
88 Results IIH and C + IIH group sh
Page 115 and 116:
90 Results group, GLUT3 mRNA signif
Page 117 and 118:
92 Results α7 nACh receptor antibo
Page 119 and 120:
GABA receptor analysis 94 Results S
Page 121 and 122:
96 Results control. D + IIH and C +
Page 123 and 124:
Discussion Glucose is the principal
Page 125 and 126:
100 Discussion The ability to sense
Page 127 and 128:
102 Discussion The Y-maze test is a
Page 129 and 130:
104 Discussion CHOLINERGIC ENZYME A
Page 131 and 132:
106 Discussion Pancreas Insulin sec
Page 133 and 134:
108 Discussion 2003). Cholinergic m
Page 135 and 136:
110 Discussion brain for learning,
Page 137 and 138:
112 Discussion hypoglycemia on brai
Page 139 and 140:
114 Discussion shows impaired expre
Page 141 and 142:
116 Discussion glycemic control is
Page 143 and 144:
118 Discussion release (Ilcol et al
Page 145 and 146:
120 Discussion al., 1992), it has t
Page 147 and 148:
122 Discussion metabolic cycles are
Page 149 and 150:
124 Discussion al., 1988). Low bloo
Page 151 and 152:
126 Discussion modulate the second
Page 153 and 154:
128 Discussion between excitation a
Page 155 and 156:
130 Discussion hypoglycemic seizure
Page 157 and 158:
132 Discussion Insulin secretion fr
Page 159 and 160:
134 Discussion hyper and hypoglycem
Page 161 and 162:
136 Discussion receptors in glucose
Page 163 and 164:
138 Discussion exacerbated by recur
Page 165 and 166:
140 Discussion Haces et al., 2010).
Page 167 and 168:
142 Discussion hypoglycemic and dia
Page 169 and 170:
144 Discussion transcription factor
Page 171 and 172:
Summary 1. Insulin induced hypoglyc
Page 173 and 174:
148 Summary specific antibodies con
Page 175 and 176:
150 Summary 16. Transcription facto
Page 177 and 178:
References Abdelmalik PA, Shannon P
Page 179 and 180:
Akwa Y, Ladurelle N, Covey F, Bauli
Page 181 and 182:
Arison RN, Ciaccio EI, Glitzer MS,
Page 183 and 184:
Balters E, Francesco M. (2002). New
Page 185 and 186:
Bettler B, Kaupmann K, Mosbacher J,
Page 187 and 188:
Boess FG, De Vry J, Erb C, Flessner
Page 189 and 190:
Brezenoff HE, Xiao YF. (1986). Acet
Page 191 and 192:
Caulfield MP, Birdsall NJM. (1998).
Page 193 and 194:
Cherubini E, Martina M, Sciancalepo
Page 195 and 196:
Cryer PE. (2002b). The pathophysiol
Page 197 and 198:
Delgado Esteban M, Almeida A, Bolan
Page 199 and 200:
Dutar P, Nicoll RA. (1989). Pharmac
Page 201 and 202:
Exton JH, Jefferson LS, Butcher RW,
Page 203 and 204:
Frier B. (2000). Hypoglycaemia—cl
Page 205 and 206:
Gerich JE, Schneider V, Dippe SE, L
Page 207 and 208:
Golding DW, Pow DV. (1990). Neurose
Page 209 and 210:
Haddad GG, Jiang C. (1993). Mechani
Page 211 and 212:
Havel PnJ, Dunning BnE, Verchere Cn
Page 213 and 214:
Hsu KS, Huang CC, Gean PW. (1995).
Page 215 and 216:
Johnson E, Deckwerth T. (1993). Mol
Page 217 and 218:
Kanjhan R, Housley GD, Burton LD, C
Page 219 and 220:
Kelley GG, Zawalich KC, Zawalich WS
Page 221 and 222:
Krnjevic K. (1993). Central choline
Page 223 and 224:
Lackovic Z, Salkovic M, Kuci Z, Rel
Page 225 and 226:
Lipton P. (1999). Ischemic cell dea
Page 227 and 228:
Mares P, Kubova H, Zouhar A, Folber
Page 229 and 230:
McCulloch DK, Raghu PK, Koerker DJ,
Page 231 and 232:
Miyakawa T, Yamada M, Duttaroy A, W
Page 233 and 234:
Nusser Z, Sieghart W, Somogyi P. (1
Page 235 and 236:
Paramo B, Hernández-Fonseca K, Est
Page 237 and 238:
Peeyush KT, Savitha B, Sherin A, An
Page 239 and 240:
Quan L, Meili G, Chang BS, Lowenste
Page 241 and 242:
Robinson R, Krishnakumar A, Paulose
Page 243 and 244:
Salkovic M, Lackovic Z. (1992). Bra
Page 245 and 246:
Scheucher A. Alvarez AL, Torres N,
Page 247 and 248:
(2002). Sulfonylurea receptor type
Page 249 and 250:
Steriade M. (1996). Arousal: revisi
Page 251 and 252:
Takayama C, Inoue Y. (2003). Normal
Page 253 and 254:
Unger J, McNeill TH, Moxley RT 3rd,
Page 255 and 256:
pentabromodiphenyl ether (PBDE 99).
Page 257 and 258:
Weiner DM, Levey AI, Brann MR. (199
Page 259 and 260:
Wredling R, Levander S, Adamson U,
Page 261 and 262:
Zhao W, Chen H, Xu H, Moore E, Meir
Page 263 and 264:
6. Anju T R, Pretty Mary Abraham, S
Page 265 and 266: Body weight (gm) 300 250 200 150 10
Page 267 and 268: Figure-3 Blood glucose levels at di
Page 269 and 270: Figure-5 Behavioural response of co
Page 271 and 272: Figure-7 Scatchard analysis of [ 3
Page 275 and 276: Figure-11 Real Time PCR amplificati
Page 289 and 290: C D + IIH Figure--25 Muscarinic M1
Page 291 and 292: Figure--27 α 7 nACh receptor expre
Page 311 and 312: Figure--47 Muscarinic M1 receptor e
Page 313 and 314: Figure--49 α7 nicotinic acetylchol
Page 315: Figure-51 Scatchard analysis of [ 3
Page 335 and 336: Figure--71 α7 nicotinic acetylchol
Page 357 and 358: C Figure--93 GABAAα1 receptor expr
Page 365 and 366: Figure-101 Real Time PCR amplificat
Page 367 and 368:
Figure-103 Real Time PCR amplificat
Page 369 and 370:
Page 371 and 372:
Page 373 and 374:
Page 375 and 376:
Page 377 and 378:
Figure—113 Muscarinic M3 receptor
Page 379 and 380:
Figure--115 GABAAα1 receptor expre
Page 381 and 382:
Figure-117 Scatchard analysis of [
Page 383 and 384:
Figure-119 Scatchard analysis of [
Page 385 and 386:
Page 387 and 388:
Page 389 and 390:
Page 391 and 392:
Page 393 and 394:
Page 395 and 396:
Figure-131 Muscarinic M1 receptor e
Page 397:
C D + IIH Figure-133 GABAAα1 recep
show all

Muscarinic M1, M3, Nicotinic,GABAA and GABAB Receptor ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?